Congenital thrombotic thrombocytopenic purpura therapy ADAMTS-13 (TAK 755) is filed in Japan.- Takeda
Takeda has filed a new drug application for ADAMTS-13 (TAK-755) in Japan for the treatment of congenital thrombotic thrombocytopenic purpura (cTTP). The submission, is supported by interim analysis data from a global pivotal PIII trial (281102) including Japanese cTTP patients as well as its follow-up study (TAK-755-3002).
cTTP is an ultra-rare inherited form of thrombotic thrombocytopenic purpura (TTP), a chronic and debilitating clotting disorder caused by a deficiency in ADAMTS13 protease. Takeda’s therapy is designed to supplement missing or deficient ADAMTS13 enzymes, and if approved, it would become the first recombinant ADAMTS13 replacement therapy for cTTP.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.